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a-Melanocyte stbnulating hormone is a neuroiDunu­
nomodulating peptide that was recendy detected in 
many non-pituitary tissues including the skin. Ac­
cordingly, epidermal cells such as keratinocytes and 
melanocytes (as well as dermal cells such as fibro­
blasts and endothelial cells), after stbnulation with 
pro-in1Iammatory cytokines or UV light, synthesize, 
and release aMSH. The eft"ects of these peptides are 
mediated through specific melanocortin (MC) recep­
tors that can be detected on iDununocompetent and 
inflammatory cells as well as on keratinocytes, mela­
nocytes, fibroblasts, and endothelial cells. In addition 
to its well known pigment-inducing capacity, aMSH 
is able to Dlodulate keratinocyte proliferation and 
dift"erentiation. Endothelial cell and fibroblast cyto­
kine production and fibroblast collagenase produc­
tion are also regulated by aMSH. The iDununosup-
T
he tridecapeptide a-melanocyte-stimulating hor­
mone (aMSH) was originally named because of its 
capacity to stimulate melanin formation in animals. 
This peptide is derived from the precursor hormone 
proopiomelanocortin (pOMC) and is highly con­
served across species (Eberle, 1988). POMC was detected primarily 
in the pituitary gland but was more recendy found to be also 
expressed in several other regions of the brain and various organs 
including immunocompetent cells and the skin (Eberle, 1988; 
Slominski et aI, 1996). The regulation of POMC gene expression is 
cell and tissue specific (Autelitano et aI, 1989; Burbach et aI, 1990). 
For example, corticotropin releasing factor induces the expression 
ofPOMC mRNA and the release ofPOMC peptides in the anterior 
pituitary, whereas it inhibits POMC production in the pars inter­
media (Autelitano et aI1990). Likewise, splicing of the three exons 
of the POMC gene transcripts di1fers between tissues. In the 
pituitary, mosdy 1.1 kb mRNA transcripts are generated, whereas 
shorter transcripts lacking exon 1 or exon 2 sequences can be 
detected in extrapituitary sites (Burbach et aI, 1990). Whether this 
is due to alternative mRNA splicing, variable length of the poly-A 
tail, or alternative transcription initiation is not yet clear. 
Several biologically active peptide hormones, such as J3-lipo­
tropin, adrenocorticotropin (ACTH), J3-endorphin, and the mela-
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pressive capacity of aMSH is Dlediated mainly 
through its eft"ects on Dlonocyte and macrophage 
functions. Accordingly, aMSH downregulates the 
production of pro-in1Iammatory cytokines and acces­
sory molecules on antigen-presenting cells. The pro­
duction of suppressor factors such as IL-l0, however, 
is upregulated by aMSH. The in vivo relevance of 
these data is documented by the finding that systemic 
application of aMSH inhibits the induction and the 
elicitation of murine contact hyper-sensitivity and 
induces hapten-specific tolerance. These findings in­
dicate that aMSH is part of the mediator network that 
regulates cutaneous in1Iammation and hyper-prolif­
erative skin diseases. Key words: injlammationlneuropep­
tUle1neuroimmunomodu14tionlepidermis. Journal of Investi­
gative Dermatology Symposium Proceedings 2:87-93, 1997 
notropins (a, /3, and 'YMSH), are derived from the POMC gene 
product. Proteolytic enzymes with distinct cleavage specificities are 
required for processing of these peptides, and recendy the prohor­
mone convertases PCl and PC2 were found to be active in this 
respect. PCl cleaves POMC into ACTH and J3-lipotropin, whereas 
PC2 generates /3-endorphin and aMSH (Benjannet et aI, 1991; 
Seidah et a11992) (Fig 1). Moreover, POMC peptides are subjected 
to post-translational modifications such as acetylation, which can 
significandy alter their biologic activity (Burbach et aI, 1990). Some 
of these modifications are regulated by neurotransmitters. Among 
others, dopamine, ')'-aminobutyric acid (GABA) , opioids, and 
histamines are capable of modifying POMC peptides (Lamacz et aI, 
1991; Tonon et al, 1993). In addition to the pituitary, however, 
other sites of the central nervous system and peripheral tissues have 
been found to process POMC in a similar fashion (Smith and 
Funder, 1988). 
The effects of aMSH and other POMC peptides on various 
tissues are transmitted via a family of specific receptors, which were 
identified recendy. These melanocortin (MC) receptors belong to 
the group of heterodimeric guanine nucleotide-binding protein 
(G-protein)-coupled receptors, all characterized by the presence of 
seven-transmembrane domains (Cone et aI, 1996). As has also been 
found for other G-protein-binding receptors, engagement of the 
receptor appears to occur in a Ca2+ -dependent manner. After 
binding of the specific ligands, the signal is transmitted via activa­
tion of adenyl cyclase and elevation of intracellular cAMP. In 
melanocytes, this is followed by activation of tyrosinase, which 
regulates melanin synthesis (Burbach and Wiegant, 1990; Halaban 
et aI, 1983). Moreover, there is recent evidence that mitogen-
1087-0024/97/$10.50 • Copyright © 1997 by The Society for Investigative Dermatology, Inc. 
87 
88 LUGER ET AL 
Exon 1 Exon 2 • Exon3 
5· .. __ I�_1"'_c'l:�·Ji_ RA�� .,...-- ; �ma ____ iliII-3' DNA 
� Transcription 
mRNA 
Figure 1. POMe transcription, translation, and processing. JP, 
joining peptide; N and C, N-terminal or C-terminal end of precu�sor 
protein, respectively; CLIP, corticotropin-like intermediate lobe peptIde; 
{3-LPH, (:I-lipotropin) 
activated protein-kinases and the transcription factor AP-1 might be 
involved in cAMP-induced melanogenesis (Englaro et ai, 1995). 
Five dUferent melanocortin receptors (MC- 1-MC-5) have been 
cloned, but it is unclear whether all of these are signal transducing. 
The various MC receptors dUfer in their tissue distribution and 
affinities for various POMC pep tides (Cone et ai, 1996). MC- 1 has 
an equally high affinity for aMSH and ACTH and is expressed by 
k ·  1 normal and malignant melanocytes, monocytes, eral:lnocytes, 
fibroblasts,2 and endothelial cells (Chhajlani and Wikberg, 1992; 
Mountjoy et ai, 1992; Bhardwaj et ai, 1997; Harl:lneyer et ai, 1997). 
MC-2 binds most melanotropic peptides, with the exception of 
(3-lipotropin, and is expressed in the brain and on adipocytes, but 
has not been found on melanoma cells (Chhajlani et ai, 1993; 
Boston and Cone, 1996). MC-3 is specific for a heptapeptide core 
shared by ACTH as well as a, (3, and yMSH and is detectable in 
brain, gut, and placenta (Gantz et ai, 1993a). MC-4 is specific for a, 
(3, and yMSH and is expressed in the brain as well in the gut (Gantz 
et ai, 1993b; Mountjoy et ai, 1994). In mice, MC-4 was recently 
identified to be crucially involved in the signaling pathway for body 
weight control because antagonism of MC-4 with the agouti 
peptide or targeted disruption of MC-4 resulted in obesity in these 
animals (Fan et ai, 1997; Huszar et ai, 1997). MC-5 binds ACTH 
and a, (3, and yMSH and is present in many tissues including brain, 
adrenal gland, adipocytes, skeletal muscle, bone marrow, spleen, 
and thymus (Gantz et al 1993a, 1994; Boston and Cone, 1996). 
Recent data demonstrated that the nucleotide sequence of MC-2, 
previously termed ACTH-R, is also identical to MC-5 because the 
mRNA sequence published for MC-5 is a co-linear but truncated 
form of the sequence published for MC-2 (Cone and Mountjoy, 
1992; Gantz et ai, 1993c, 1994). With regard to the skin, there is 
evidence that both POMC peptides and at least some of the POMC 
receptors are expressed in the epidermal and in the dermal com­
partment of the skin 1, 2 (Bhardwaj and Luger, 1994; Jiang et ai, 
1996; Ermak and Slominski, 1997; Hartmeyer et ai, 1997). Al­
though little is known about the functional relevance of most 
POMC peptides in the skin, significant biologic effects were already 
identified for aMSH, which was found to modulate epidermal cell 
functions and to be a potent regulator of immune and inflammatory 
reactions. 
1 Bhardwaj RS, Becher E, Mahnke K, Hartlneyer M, Scholzen T, 
Schwarz T, Luger TA: Evidence of the expression of a functional melano­
cortin receptor 1 by human keratinocytes.} Invest Denllato1106:817, 1996 
(abstr). 
2 Bohm M, Schulte U, Hartlneyer M, Scholzen T, Becher E, Luger TA: 
Human dermal fibroblasts express melanocortin-1 receptors and respond to 
alpha-melanocyte stimulating hormone with secretion of interleukin-6 and 
interleukin-8.} Invest Dennatol108:S93, 1997 (abstr). 
JID SYMPOSIUM PROCEEDINGS 
PRODUCTION OF aMSH AND EXPRESSION OF MC 
RECEPTORS IN THE SKIN 
In 1983, a study performed by A.J. Thody et al demonstrated that 
inlmunoreactive aMSH was detectable in human skin and the skin 
of several other mammals. The highest concentration of aMSH was 
found in the epidermis. The finding that the skin still contained 
considerable amounts of aMSH in hypophysectomized rats sug­
gested that the pituitary is not the only source of aMSH bioactivity 
found in the skin (Thody et ai, 1983). Meanwhile, POMC mRNA 
and various POMC pep tides have been shown to be present in 
normal and diseased skin, and several cellular compartments within 
the epidermis and dermis were identified as a source of aMSH and 
other POMC peptides (Slominski et ai, 1993b; Bhardwaj and Luger, 
1994; Slominski et ai, 1996; Wintzen and Gilchrest, 1996). So far, 
however, no correlation has been found between the degree of 
POMC expression and any skin disease or tumor, although these 
studies are far from complete. 
It is now well established that melanocytes and melanoma cells of 
human and murine origin express mRNA specific for POMC and 
release POMC peptides including aMSH, ACTH, and (3-endorphin 
(Lunec et ai, 1990; Slominski, 199 1) (Table I). POMC synthesis as 
well as aMSH and ACTH release by murine melanoma cells is 
stimulated upon treatment with tumor promoters ( 12-0-tetrade­
canoyl-phorbol-13-acetate), ultraviolet light (UVB), or aMSH 
itself (Chakraborty et ai, 1995). Although it remains unclear 
whether aMSH stimulates melanogenesis in human skin, a poten­
tially important role of aMSH in melanocyte biology is suggested 
by studies demonstrating binding sites specific for aMSH on 
melanocytes and melanoma cells (Eberle et ai, 1993) (Table I). In 
this respect, MC-1 mRNA expression has been detected in mela­
nocytes and melanoma cells (Chhajlani and Wikberg, 1992; 
Mountjoy et ai, 1992; Chakraborty et ai, 1995; Suzuki et ai, 1996). 
Depending on the melanocyte cell line investigated, aMSH was 
found to either up- or downregulate the expression of its receptor. 
Other stimuli such as retinoic acid, UVB, interferon-a, interfer­
on-(3, interferon-I', and aMSH have also been shown to upregulate 
MC-1 receptor expression on melanocytes and melanoma cells 
(Chakraborty et ai, 1990; Siegrist et ai, 1994; Chakraborty et ai, 
1995). 
Melanocytes, however, do not appear to be the only source of 
POMC peptides and their receptors in the skin. Several studies have 
demonstrated the production of POMC peptides by epidermal cells 
other than melanocytes. Accordingly, keratinocytes, Langerhans 
cells, and murine Th 1 + dendritic epidermal cells have all been 
shown to express POMC-specific mRNA and to release bioactive 
aMSH (Morhenn, 1991; Farooqui et ai, 1993; Schauer et ai, 1994; 
Farooqui et ai, 1995; Wintzen and Gilchrest, 1996) (Table I). 
POMC peptides are usually not found in normal human skin except 
for keratinocytes of scalp hair follicles. By inlmunohistochemistry, 
Table I. Production of POMC Peptides and 
Melanocortin Receptor Expression in the Skin" 
Melanocortin 
POMC Pep tides Receptor 
Keratinocyte aMSH,ACTH MC-1 
{:ILPH, {:I-endorphin 
Melanocyte aMSH,ACTH MC-1 
{3-endorphin 
Langerhans cell aMSH n.d. 
Monocyte aMSH MC-1 
ACTH 
Macrophage aMSH MC-1 
Endothelial cell aMSH MC-1 
Fibroblast aMSH,ACTH MC-1 
Adipocyte n.d. MC-2 
MC-S 
Mast cell aMSH,ACTH MC-1 
• flLPH, /3-lipotropic honnone; n.d., not detennined. 
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Figure 2. Effect of the proopiomelanocortin (POMC) peptide aMSH (a melanocyte stimulating hormone) on the function of epidermal and 
dermal cells. (MC, melanocortin receptor; IL, interleukin; LTC4, leukotriene C4; �, induction; -i, inhibition) 
however, intense staining for melanotropins or J3-lipotropins can be 
observed in lesional skin of inflammatory skin diseases or tumors 
(Slominski et ai, 1993b). In contrast, selective expression of J3-en­
dorphin in sebaceous glands was detected in normal murine skin, 
and POMC expression in mouse skin was found to be hair 
cycle-dependent. Accordingly, tyrosinase mRNA, POMC mRNA, 
and /3-endorphin protein, as well as MC-1R and corticotropin 
hormone receptor type 1, were detected in mice in the anagen but 
not the telogen phase of the hair cycle (Slominski et ai, 1992; Ermak 
and Slominski, 1997). These data suggest a regulatory role of 
POMC peptides in the function of skin appendages in vivo. 
In vitro, transformed murine and human keratinocyte cell lines as 
well as normal human keratinocytes have been reported to produce 
several POMC peptides including aMSH, ACTH, /3-endorphin, 
and /3-lipotropic hormone in certain experimental conditions 
(Schauer et ai, 1994; Chakraborty et ai, 1995; Wintzen and 
Gilchrest, 1996). In accordance with inununohistochemical data 
described above, in vitro studies also revealed that normal cells 
usually do not express significant amounts ofPOMC mRNA. Upon 
stimulation with tumor promoters (phorbol myristate acetate) or 
UV light, however, POMC-specific mRNA was readily detectable 
by northern blot analysis in normal keratinocytes as well as in 
epidermoid carcinoma cell lines (Schauer et ai, 1994; Chakraborty et 
ai, 1995; Wintzen and Gilchrest, 1996). Among various cytokines 
investigated, only interleukin-l (IL-1) has been found to enhance 
aMSH production by human keratinocytes. Keratinocyte-derived 
POMC mRNA has a size of 1.1 kb, which is similar to the full size 
transcript reported in pituitary tissue (Schauer et ai, 1994). Among 
dermal cells, human dermal vascular endothelial cells and fibro­
blasts were found to express POMC mRNA and to release POMC 
peptides. POMC production in endothelial cells was upregulated 
upon treatment with IL-1/3 or UV light.3 In fibroblasts, transform­
ing growth factor-/3 strongly inhibited POMC transcription, 
whereas tumor necrosis factor-a exerted a stimulatory activity on 
POMC mRNA levels (Teofoli et aI, 1997). 
Among the different melanocortin receptors, only mRNA spe­
cific for MC-l could be detected in normal and transformed 
keratinocytes, suggesting that aMSH is the most relevant of the 
POMC peptides in the regulation of keratinocyte functions, since it 
is the major ligand of MC_1.1 In addition, MC-1 expression in 
keratinocytes was upregulated upon treatment with UVB 
(Chakraborty and Pawelek, 1993; Jiang et ai, 1996). Likewise, 
human dermal microvascular endothelial cells and a transformed 
microvascular endothelial cell line (HMEC-l) were recently re­
ported to express MC-1, whereas other melanocortin receptors 
could not be detected on endothelial cells (Hartmeyer et ai, 1997). 
aMSH and IL-1/3 were found to upregulate the constitutive 
expression of MC-l on endothelial cells. Moreover, adipocytes 
expressed MC-2 and MC-5, whereas dermal fibroblasts express 
only MC_12 (Boston and Cone, 1996) (Table I). Thus, a number 
of different cutaneous cells produce POMC peptides and/or their 
receptors, strongly suggesting a physiologic role of these mediators 
in cutaneous biology (Fig 2). 
3 Scholzen T, Brzoska T, Hartmeyer M, Fastrich M, Becher E, Schwarz 
T, Luger T A: Expression of proopiomelanocortin, melanocortin receptor 1, 
and cytokines is differently modulated upon irradiation wid! UV A-l light. 
Arch Dennatol Res 289:A51, 1997 (abstr). 
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FUNCTIONAL PROPERTIES OF POMC PEPTIDES AND 
THEIR RECEPTORS IN THE SKIN 
There is ample evidence that aMSH is a relevant signal that 
controls different melanocyte functions. In this respect, aMSH 
modulates proliferation, differentiation, and cytokine production by 
melanocytes in vitro (Herlyn et ai, 1988; Hirobe, 1992; De Luca et ai, 
1993; Armstrong et ai, 1994). In melanoma cells, aMSH has been 
shown to stimulate melanogenesis, dendrite formation, and attach­
ment to laminin. Moreover, it inhibits or stimulates melanoma cell 
proliferation, depending on the culture conditions and the cell line 
studied (Pawelek, 1985; Eberle, 1988; Herlyn et ai, 1988; Hunt et ai, 
1993). There is recent evidence that certain protein kinases C are 
involved in the regulatory effects of aMSH on melanogenesis as 
well as on differentiation and proliferation of melanocytes because 
they were found to be upregulated by aMSH or after ultraviolet 
irradiation (Oka et ai, 1996; Park and Gilchrest, 1993). Finally, 
DNA fragments generated during the repair ofUV-induced pho­
toproducts have been demonstrated to enhance the effects of 
aMSH on melanoma cells and also to enhance the binding of 
aMSH to its receptor. Thus, UV-mediated DNA damage appears 
to enhance tyrosinase mRNA expression and melanogenesis by 
stimulation of aMSH production and enhancement of aMSH 
binding to the MC receptors (Eller et ai, 1996). As further empha­
sized below, aMSH affects cytokine production, and conversely, 
aMSH production is also affected by cytokines. Taken together, 
these findings not only support a role for aMSH in UV -mediated 
melanogenesis but also suggest that modulation of aMSH and its 
receptor by cytokines may be responsible for post-inflammatory 
hyper-pigmentation in many inflammatory skin conditions (Fig 2). 
Additional data indicate that MC-1 could also be one of the 
genes responsible for pigmentation because mammalian coat colors 
were found to be determined by alleles at an extension locus that 
also encodes MC-1 in mice (Robbins et ai, 1993). Moreover, 
agouti, which is another coat color-regulating gene locus, encodes 
for a protein that is a functional antagonist for MC-1 and MC-4 (Lu 
et al ,1994). Accordingly, the coat-darkening effects of aMSH are 
inhibited by agouti protein (Hunt and Thody, 1995). Thus, analysis 
of potentially existing multiple MC-1 alleles at the molecular level 
may help to define pigmentary disorders and perhaps also mela­
noma susceptibility (Robbins et ai, 1993). 
There is evidence that POMC peptides such as aMSH are also 
involved in the regulation of keratinocyte biology. In this respect, 
aMSH and other POMC peptides were found to modulate kerati­
nocyte proliferation and differentiation as well as to enhance sebum 
secretion (Slominski et ai, 1993a; Orel et ai, 1997). Moreover, 
aMSH suppresses heat shock protein expression in differentiated 
but not in undifferentiated keratinocytes, and aMSH-treated kera­
tinocytes were found to be more sensitive to oxidative stress. 
Because aMSH is released by keratinocytes following injurious 
stimuli, these data indicate that aMSH may affect keratinocyte 
survival after injury by regulating their own cytoprotective protein 
equipment in an autocrine fashion (Orel et ai, 1997). 
The effect of aMSH or other POMC peptides on cells residing in 
the dermis has not been fully investigated. Dermal aMSH may be 
derived from the epidermis, dermal fibroblasts, or inflammatory 
cells infiltrating the dermis such as monocytes or lymphocytes 
(Bhardwaj and Luger, 1994; Lyons and Blalock, 1995; Rajora et ai, 
1996; Teofoli et ai, 1997). It has been known for a long time that 
POMC pep tides including aMSH have lipolytic activity, but only 
recently were adipocytes shown to express the melanocortin 
receptors MC-2 and MC-5 (Boston and Cone, 1996). Synthesis 
of collagenase/MMP-1 by human fibroblasts has been reported 
to be upregulated upon treatment with aMSH (Kiss et ai, 1995), 
and MC-1 has been recently reported on dermal fibroblasts2• 
Because aMSH production is induced by UV irradiation, it may 
contribute to the loss of interstitial collagen during cutaneous 
photoaging. 
JID SYMPOSIUM PROCEEDINGS 
IMMUNOREGULATORY EFFECTS OF POMC-DERIVED 
PEPTIDES 
POMC gene products have been demonstrated to affect immune 
and inflammatory reactions in several ways. Several studies showed 
that aMSH antagonizes the effects of pro-inflammatory cytokines 
such as IL-1a, IL-1�, IL-6, and tumor necrosis factor-a (Catania 
and Lipton, 1993). Systemic administration of aMSH was found to 
decrease IL-1-induced fever, leukocytosis, migration of neutro­
phils, and induction of acute phase proteins (Cannon et ai, 1986; 
Lipton and Catania, 1997). aMSH also downregulates the produc­
tion of interferon-y in lymphocytes stimulated by mitogen or 
antigen (Luger et ai, 1993; Taylor et ai, 1994). Moreover, aMSH 
selectively induces the production of IL-10 by peripheral blood 
monocytes (Bhardwaj et ai, 1996). Several studies indicate that the 
immunomodulatory and anti-inflammatory effects of aMSH are 
mediated by the C-terminal region of aMSH because administra­
tion of a truncated C-terminal tripeptide is sufficient to induce these 
effects (Catania and Lipton, 1993; Bhardwaj et ai, 1996). Taken 
together, these studies indicate that several pro-inflammatory cy­
tokines are downregulated by aMSH, whereas the production of 
the anti-inflammatory cytokine IL-10 is stimulated by aMSH, 
suggesting that aMSH may have an important role in suppressing 
immune and inflammatory reactions (Fig 2). 
Other studies have investigated the expression of binding sites 
specific for aMSH and other POMC peptides on inflammatory and 
immunocompetent cells. Monocytes and neutrophils were found to 
express MC-1 mRNA, and aMSH inhibited the chemotaxis of 
neutrophils in IL-8 and f-met-Ieu-phe gradients in a concentration­
dependent manner (Chiao et ai, 1996; Lipton and Catania, 1997). 
Moreover, binding sites for aMSH and ACTH were detected on 
human monocytes, monocytic cell lines, and murine macrophages. 
The presence of an aMSH-specific receptor on monocytes was 
confirmed by the detection of MC-1 mRNA expression by these 
cells, whereas transcripts for the other known MC receptors could 
not be detected on mononuclear cells (Star et ai, 1995; Rajora et ai, 
1996; Bhardwaj et ai, 1997). Treatment of monocytes with either 
mitogen or endotoxin upregulated aMSH receptor expression on 
human monocytes. Moreover, there is evidence that MC-1 expres­
sion on monocytes is altered during monocyte activation and 
maturation (Bhardwaj et ai, 1997) (Fig 2). 
Additional studies addressed the question whether another means 
by which aMSH might exert its immunomodulatory effects is by 
regulating the expression of surface molecules in immunocompe­
tent cells. There is evidence at the transcriptional as well as 
translational level that aMSH downregulates the expression of 
MHC class I antigens on monocytes and keratinocytes. In contrast, 
the expression of MHC class II antigens and intercellular adhesion 
molecule 1 (ICAM-1) does not appear to be affected by aMSH 
(Kock et ai, 1991; Luger et ai, 1993). Surface expression of CD80 
(B7-1) on LPS-treated monocytes was also not substantially altered 
in the presence of aMSH, but aMSH was found to significantly 
inhibit the expression of CD86 (B7-2) on these cells (Bhardwaj et 
ai, 1997). These data suggest that aMSH is capable of downregu­
lating accessory molecules on antigen-presenting cells. Thus, in 
certain biologic conditions, aMSH may function as one of the 
signals responsible for anergy or tolerance induction. 
Moreover, POMC peptides have been demonstrated to be 
involved in the regulation of antibody synthesis by B-lymphocytes. 
aMSH, however, appears to act predominantly in concert with 
other B cell-stimulatory cytokines and, depending on which cyto­
kines are present, has up- or downregulatory effects on antibody 
synthesis. For example, aMSH and ACTH were shown to modu­
late IL-4 and anti-CD40-mediated IgE release by human peripheral 
blood mononuclear cells. At physiologic concentrations, ACTH 
and aMSH increase IgE synthesis, whereas higher concentrations of 
these peptides strongly inhibit 19B synthesis. Most interestingly, the 
IgE-inducing capacity of POMC peptides again seems to be depen­
dent on the presence of monocytes (Aebischer et ai, 1994, 1995). 
Thus, POMC peptides could be involved in the pathogenesis of 
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allergic diseases and may represent the postulated neuroendocrine 
arm in diseases such as atopic eczema. This notion is further 
supported by the recent finding that aMSH is able to significandy 
enhance the release of histamine and leukotriene C4 from human 
cutaneous mast cells.4 
Several publications demonstrate that aMSH also has important 
effects on cutaneous immune and inflammatory responses such as 
contact hypersensitivity and irritant dermatitis. For example, topical 
application of aMSH was reported to suppress the sensitization and 
elicitation phases of the contact hyper-sensitivity response in mice 
(Rheins et ai, 1989). Similarly, systemic administration of aMSH 
was found to inhibit both the induction and elicitation of murine 
contact hyper-sensitivity and also resulted in the induction of 
hapten-specific tolerance. The inhibitory effect of aMSH on con­
tact hyper-sensitivity may be mediated via induction of immuno­
suppressive cytokines such as IL-10 because the downregulatory 
effects of aMSH could be blocked by administration of anti-IL-10 
antibodies. In addition, preliminary data suggest that in mice, a 
single systemic application of aMSH results in significant and 
long-lasting elevation of IL-10 plasma levels (Bhardwaj and Luger, 
1994; Grabbe et ai, 1996). On the other hand, aMSH was found to 
enhance the synthesis and release of the chemokine IL-8 by 
endothelial cells, whereas the production of other pro-infiamma­
tory cytokines such as IL-1 or IL-6 was not affected (Hartmeyer et 
ai, 1997). Thus, inflammatory stimuli may lead to aMSH produc­
tion in the skin, which may then modulate leukocyte-endothelial 
cell interactions via stimulation of the production of chemokines. 
Because chemokines such as IL-8 have been shown to be potent 
angiogenic factors, inducing endothelial cell chemotaxis in vitro and 
neovascularization in vivo, aMSH may also be involved in the 
regulation of angiogenesis during wound healing or trunorigenesis 
(Strieter et ai, 1995<i, 1995b) (Fig 2). These findings indicate that 
aMSH may be a significant regulatory molecule in cutaneous 
immune responses in vivo. 
aMSH may also function as a systemic immunoregulatory me­
diator. indeed, increased levels of aMSH have been detected 
during the course of chronic inflammatory responses such as 
arthritis, viral and parasitic infections, and inflammatory skin dis­
eases such as atopic eczema, supporting a possible in vivo relevance 
of melanotropins as immunomodulating agents (Duvaux Miret et al 
1992; Blalock, 1994; Catania et ai, 1994a, 1994b; Lipton et ai, 1994; 
Glinski et ai, 1995). Moreover, elevated plasma aMSH is detectable 
in patients following exposure to UV light and in patients with 
metastatic melanoma, further supporting a potential systemic effect 
of skin-derived POMC peptides (Holzmann et ai, 1983; Spiro et ai, 
1987; Schwartze and Fiedler, 1994). Systemic application of aMSH 
was found to inhibit the development of adjuvant-induced arthritis 
in rats (Ceriani et ai, 1994). In another animal model, aMSH was 
able to prevent endotoxin-mediated liver inflammation by inhibit­
ing the production of pro-inflammatory cytokines and chemokines 
(Chiao et ai, 1996). In humans, a correlation between aMSH 
plasma levels and survival of patients with AIDS was reported 
(Catania et ai, 1993). These findings further support the concept 
that aMSH has significant immunomodulatory functions and par­
ticipates in a regulatory network that controls the outcome of 
immune responses, possibly acting via alteration of monocyte 
functions. 
CONCLUSIONS 
There is accumulating evidence that a number of POMC peptides 
as well as their respective receptors are produced in the skin 
following injury such as UV irradiation or in inflammatory and 
neoplastic diseases (Fig 2). The findings suggest that these mole­
cules participate in the regulation of cutaneous inflammation and 
possibly also in the pathogenesis of skin diseases. Since the MC-1 
4 Pfrommer C, Kunz C, Lnger T, Henz BM: Proopiomelanocortin 
products enhance histamine and L TC4 release from the human cell line 
HMC 1 and human cutaneous mast cell in vitro.] Invest Dennatol107: 507, 
1996 (abstr). 
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receptor, which is specific for aMSH, is the major melariocortin 
receptor detectable on epidermal, dermal, or inflammatory cells, 
aMSH seems to be the most relevant of the POMC peptides for 
modulating the skin immune system. Additional studies are needed, 
however, to determine more exactly the mode of action of aMSH 
during the pathogenesis of skin diseases and to evaluate its potential 
as an anti-inflammatory agent in the treatment of inflammatory skin 
diseases. 
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